Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 17/20 | 0.62 |
| ▸ | CCR2 | P41597 | 1/20 | 0.62 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1629881 | 0.88 | CCR9 (0.64) | CCR9CCR2HSD17B2 | |
| SCHEMBL1630576 | 0.87 | CCR9 (0.59) | CCR9CCR2HSD17B2 | |
| SCHEMBL345093 | 0.81 | CCR9 (0.68) | CCR9CCR2HSD17B2 | |
| SCHEMBL2616510 | 0.79 | CCR9 (0.66) | CCR9CCR2HSD17B2 | |
| SCHEMBL1630763 | 0.77 | CCR9 (0.63) | CCR9CCR2HSD17B2 | |
| SCHEMBL1631935 | 0.77 | CCR9 (0.66) | CCR9CCR2HSD17B2 | |
| Vercirnon SCHEMBL342225 | 0.77 | CCR9 (1.00) | CCR9CCR2HSD17B2 | |
| SCHEMBL2616502 | 0.76 | HSD17B2 (0.59) | CCR9CCR2HSD17B2 | |
| SCHEMBL2616498 | 0.76 | CCR9 (0.79) | CCR9CCR2HSD17B2 | |
| Vercirnon SCHEMBL15766988 | 0.76 | CCR9 (0.98) | CCR9CCR2HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101097-A9 | ARYL SULFONAMIDES | UNGASHE SOLOMON (US) | 2012-04-26 | — | — | US | disclosed |
| US-20110201610-A1 | ARYL SULFONAMIDES | UNGASHE SOLOMON | 2011-08-18 | — | — | US | disclosed |
| US-7932252-B2 | CCR9 chemokine receptor modulators; treating inflammatory and immune diseases; inhibit the binding of chemokines, such as TECK (thymus-expressed chemokine), to the CCR9 receptor; 1-arylsulfonamido-2-aryl(alkyl)benzene compounds | CHEMOCENTRYX, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-20080161345-A1 | Aryl Sulfonamides | CHEMOCENTRYX, INC. | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201610-A1 | ARYL SULFONAMIDES | CCR2, CCL2, CX3CR1 | CCR9 13/4885CCR2 1/4885HSD17B2 1750/4885 |
| US-20080161345-A1 | Aryl Sulfonamides | CCR2, CCL2, CX3CR1 | CCR9 13/4885CCR2 1/4885HSD17B2 1750/4885 |
| US-20120101097-A9 | ARYL SULFONAMIDES | CCR2, CCL2, CX3CR1 | CCR9 13/4885CCR2 1/4885HSD17B2 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.